Scottish-based pharma company gains US approval for new drug

/, Life Sciences, National/Scottish-based pharma company gains US approval for new drug

Scottish-based pharma company gains US approval for new drug

Kyowa Hakko Kirin Co., Ltd., (Kyowa Kirin) has gained approval from the U.S. Food and Drug Administration (FDA) for its blood cancer treatment Poteligeo (mogamulizumab-kpkc) for the treatment of adult patients.

Using the proprietary POTELLIGENT technology, the amount of fucose in the sugar chain structure of Poteligeo is reduced, which enhances the antibody dependent cellular cytotoxicity (ADCC).

[adbutler zone_id='297765′]

Mitsuo Satoh Ph.D., Executive Officer, Vice President Head of R&D Division of Kyowa Hakko Kirin said “I believe the approval is very good news for patients who have been suffering from mycosis fungoides (MF) or Sézary syndrome (SS) in the US.

“Since this antibody was discovered through our cutting-edge R&D activity, it is also another important achievement for Kyowa Hakko Kirin in leaping forward to become a global specialty pharmaceutical company.”

Jeffrey S. Humphrey, MD, President of Kyowa Kirin Pharmaceutical Development, Inc said “Mycosis fungoides (MF) and Sézary syndrome (SS) can be disfiguring, and debilitating. MAVORIC, the largest study of systemic therapy ever conducted in MF and SS, showed that mogamulizumab prolonged progression-free survival compared to vorinostat in patients with relapsed or refractory MF or SS. We look forward to the publication of MAVORIC’s primary results and to ongoing scientific exchange within the medical and academic communities.”

Because CTCL manifests itself in skin lesions, it is often mistaken for other non-critical skin conditions, which can delay conclusive diagnosis and treatment options. MF and SS are the two most common subtypes of CTCL. MF is the most common subtype, accounting for 50-70% of cases. It is a slow progressing form of lymphoma that can involve the skin, blood, lymph nodes and organs, and may be associated with severe infections. SS accounts for approximately 3% of CTCL cases and is a more aggressive, leukemic form of CTCL.

The FDA approval of Poteligeo is supported by the MAVORIC (Mogamulizumab anti-CCR4 Antibody Versus ComparatOR In CTCL) study, which is the largest randomized trial in MF and SS and the first pivotal trial in CTCL to use PFS as a primary endpoint. MAVORIC was a Phase 3 open-label, multi-center, randomized study of mogamulizumab versus vorinostat in patients with MF and SS who have failed at least one prior systemic treatment. The study was conducted in the U.S., Europe, Japan and Australia, and randomized a total of 372 patients to mogamulizumab or vorinostat. The results showed that mogamulizumab demonstrated significantly superior PFS at a median of 7.6 months [95% CI:  5.6, 10.2] compared to 3.1 months with vorinostat [95% CI:  2.8, 4.0], [hazard ratio 0.53: 95% CI: 0.41, 0.69; p<0.001]. The confirmed overall response rate for mogamulizumab and vorinostat was 28% and 5%, respectively (p<0.001).

FDA granted Poteligeo Breakthrough Therapy Designation for the treatment of MF and SS in adult patients, and evaluated Poteligeo with Priority Review, which is reserved for drugs that treat a serious condition and, if approved, would provide a significant improvement in treatment safety or effectiveness.

Kyowa Kirin International PLC, a Kyowa Hakko Kirin Group company, will be responsible for commercializing Poteligeo in the U.S. and this is planned to commence in the fourth quarter of 2018. A Marketing Authorization application for mogamulizumab is currently under review by the European Medicines Agency.

The Kyowa Hakko Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.

Subscribe to our daily newsletter to get stories like this delivered directly to your inbox

By |2018-08-09T09:00:30+00:00August 9th, 2018|Business News, Life Sciences, National|Comments Off on Scottish-based pharma company gains US approval for new drug

About the Author:

SBNN